ROARABLE
FREE $100K
My Trading Account β†’
β–Ύ
Trading Profile Active
Active Trader
Verified Trader
⚑ My $100K Trading Account β†’ β˜… My Saved Watchlist β†’
🟒 My $100K Account β†’ Today Screener Big Ideas Track Record πŸ’° $100K Arena 🎲 Predictions πŸ›οΈ Insiders 8 Analysts
Stock Ratings / Health Care / OTLK
HUMA (30) AVXL (32) ARMP (32) VYGR (15) ⌘ Pro Terminal β†’

Outlook Therapeutics Inc. (OTLK) β€” RQD Stock Rating Cockpit

$0.47 +0.24% NASDAQ β€’ Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $0.47

Outlook Therapeutics Inc. (OTLK) carries a Roarable Rating of D- (Sell) with 35/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D- β€’ RED ALERT Cap $114.0M
πŸ“€ Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚑ INSTANT AI QUANT PREVIEW β€’ $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on OTLK Below β€” or Connect Your Own ChatGPT / Claude
πŸ€– Mara Quenwick β€’ AI Quant Lead (Click for Instant Brief) Is OTLK stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
β–Ό

As of 2026-11-03, Outlook Therapeutics Inc. (NASDAQ: OTLK) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 35/100 at a spot price of $0.47 (+0.24% 1D, market cap $114.0M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 9/20, SEC Balance-Sheet Forensics 8/20, FRED Macro Regime Fit 7/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, OTLK ranks #599 in composite RQD confidence.

βœ“ Pre-computed one-to-many AI Quant brief
πŸ€– Ellis Vennor β€’ AI Peer & Flow Quant (Click for Instant Brief) How does OTLK compare to HUMA and AVXL in the Health Care sector?
β–Ό

Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), OTLK carries a Roarable D- (35/100 RQD), trailing P/E of N/A, gross margin of 4.0%, and ROIC of -35.0%. By comparison, HUMA (Humacyte Inc.) holds a E grade (30/100 RQD, P/E N/A, ROIC -35.0%, cap $114.2M) and AVXL (Anavex Life Sciences Corp.) posts a E grade (32/100 RQD, P/E N/A, ROIC -35.0%, cap $110.3M). Among the 5-stock peer group, OTLK leads on earnings multiple (N/A) while OTLK leads on capital efficiency (-35.0% ROIC).

βœ“ Pre-computed one-to-many AI Quant brief
πŸ€– Gideon Ashmere β€’ AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for OTLK?
β–Ό

Per OTLK's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-09-30, CIK 0001649989), Outlook Therapeutics Inc. generated $1.4M in revenue (-99.3% YoY), -$62.4M in net income, and -$51.8M in free cash flow against $18.2M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

βœ“ Pre-computed one-to-many AI Quant brief
πŸ€– AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists β€” not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
πŸ›‘οΈ Portfolio Crash X-Ray
EXT / AFTER-HRS: $0.47 (-0.15%)🧬 Dilution Drag (+1.28% YoY Shares)βš™οΈ Cash Engine: 8/20 (D-) β€’ 0% FCF Margin
Verify 90D Bucket Audit β†’
πŸ“Š Historical Track Record Warning: Scores below 50 (35/100 Β· D-) historically underperformed SPY in 71% of rolling 90-day windows (-8.5% avg 90D alpha vs SPY β€’ 29.0% hit rate).
Audit Bucket Track Record β†’
RQD QUANT TACHOMETERRED ALERT β€’ D-
025507510035
3-of-3 Quant Analysts Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) β€” not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR RQD RADARRw E Β· Rk D-
Cash (8)Whales (9)SEC (8)Macro (7)CEO (3)
Each axis scored 0–20
12M PRICE TARGET CONE-10.6% Base Target
$3 Bull$0 Base$0 Bear
πŸ“¬ FREE OTLK RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: β€” (No Active Options Snapshot on file for OTLK)Realized 20D OHLCV Swing Band: Β±12.5%
Deterministic 5-Pillar Attribution (35/100 Composite)
πŸ” WHY OTLK SCORES 35/100 (D-) β€” TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
β–² #1 Bullish Driver: Whale & Options Positioning+9/20 pts (26% of score)

20D Institutional Volume Accumulation (Β±12.5% realized swing band)

β–² #2 Bullish Driver: Cash Engine Quality+8/20 pts (23% of score)

SEC XBRL FY 2025 (10-K): 0% FCF Margin ($0 FCF) & 4% Gross Margin

β–Ό #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+1.28% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

πŸ“ˆ PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 β†’ Q2 β†’ Q3 β†’ Current
Q1 (-3Q)
43
Grade D$0.58-15.5% Next Q
Q2 (-2Q)
40
Grade D$0.49+4.1% Next Q
Q3 (-1Q)
38
Grade E$0.51-7.8% Next Q
Current
35
Grade D-$0.47-8.5% Hist 90D Ξ±
Trajectory: D (43) β†’ D- (35)Full Audit β†’
βš”οΈ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

βš”οΈ Adversarial Opposing Case: What Could Spark a OTLK Turnaround Squeeze

Gideon Ashmere Forensic Desk β†’

While OTLK currently carries a cautious 35/100 (D-) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

πŸš€ Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

πŸš€ Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($0.60) and Max Pain ($0.49) forces dealer call-delta covering toward $2.67.

πŸš€ Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+1.28% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $OTLKβ€’ $2.4M Crowd Pool β€’ Kalshi / Polymarket Composite
Contract: β€œOTLK Beats Next Quarter EPS Consensus (Dec 29, 2026) & Holds Above 200D SMA”
YES 35%NO 65%Trade / Inspect Odds β†’
RSI-14 MOMENTUMNEUTRAL RANGE
3730 Oversold Β· 70 Hot
ALTMAN-Z SHIELDFORTRESS SAFE (>3.0)
3.80>3.0 Fortress Safe
PIOTROSKI F-SCOREWEAK QUALITY (1–4)
2 / 99-Pt Accounting
52-WEEK LASER RANGE13% OF RANGE
L: $0$0.47H: $3
1. Money & Cash Health● WEAK
Are profits real cash in the bank?

Weak cash conversion or heavy valuation strain compared to actual cash earned.

Factor Grade: D-RQD 8 / 20
2. Big Money & Insiders● TRIMMING
Are whales & executives buying or selling?

Insiders and big institutional desks have been trimming shares rather than stepping up to buy.

Factor Grade: ERQD 12 / 40
3. Hidden Risks & Market Weather● WARNING
SEC fine-print scan & interest-rate fit

High sensitivity to tight interest rates or new risk warnings added to recent SEC annual filings.

Factor Grade: D-RQD 15 / 40
MULTI-MODEL QUANT PANEL DELIBERATION

3-of-3 Quant Analysts Bearish Warning on OTLK

Cash & Moat Bull AI
ROIC & Free Cash Flow Model
BEARISH (40)

-35.0% ROIC with 4.0% gross margin and 2.80% FCF yield.

SEC Forensic Auditor AI
10-K Accruals & Altman-Z Guard
BEARISH (40)

Altman-Z 4.20 and Piotroski 2/9 pass balance-sheet audit.

Whale & Macro Hawk AI
Options Skew, 13F & Fed NetLiq
BEARISH (32)

12/40 institutional & smart-money positioning score with 7/20 macro alignment.

Bull Case: Why Buyers Like OTLK
  • βœ“Established market leader in Health Care with deep daily trading liquidity.
Bear Case: What Could Go Wrong
  • !Company executives have done more routine share selling than personal cash buying lately.
  • !Sensitive to high interest rates and tighter Federal Reserve market liquidity.
  • !Recent SEC filings added new risk-factor disclosures that warrant keeping an eye on margins.
ON-DEMAND RQD QUANT WORKSHOP β€’ SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring OTLK)

  • βœ“Walkthrough of OTLK's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • βœ“3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • βœ“Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) β†’$100K Arena
OTLK // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +80.77%⚑ TESTING RESISTANCE
2026-11-03O $0.50H $0.50L $0.47C $0.47VOL 4.79M
RES: $0.52SUP: $0.39SMA50: $0.60SMA200: $0.66
$2.00$1.51$1.03$0.54$0.06RES $0.52SUP $0.39$0.472026-05-042026-06-172026-08-042026-09-172026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

OTLK Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

πŸ¦‹ OTLK Butterfly Map β†’ + Track OTLK β†’
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth

vs. -99.3% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on OTLK today. View full Setup Ledger β†’

πŸ¦‹ Documented & Second-Order Butterfly Connections Open Graph β†’

No direct multi-tier Butterfly edges indexed yet for OTLK. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for OTLK today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk β†’
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT β€’ SEC EDGAR XBRL Γ— RQD PEER BENCHMARK

πŸ“Š Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (OTLK)

Health Care Rank #599 of 1015 βš”οΈ HUMA vs OTLK Full Matrix β†’

1. Head-to-Head Health Care Peer Comparison (OTLK vs. HUMA, AVXL, ARMP, VYGR)

Industry: Biotechnology: Biological Products (No Diagnostic Substances) (156 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Outlook Therapeutics Inc. (OTLK) ranks #599 by composite RQD confidence (35/100, grade D-) and #633 by equity capitalization ($114.0M). Within this direct 5-issuer industry benchmark cohort, OTLK leads on earnings valuation at N/A trailing P/E, while OTLK leads on capital efficiency and profitability with -35.0% ROIC and 4.0% gross margin. OTLK currently leads its immediate peer cohort in composite quantitative strength at 35/100 (D-).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
OTLK ACTIVE
Outlook Therapeutics Inc.
D- 35/100 β€” 4.0% -35.0% +0.24% $114.0M Benchmark Subject
HUMA
Humacyte Inc.
E 30/100 β€” -30.0% -35.0% -3.19% $114.2M /huma-vs-otlk β†’
AVXL
Anavex Life Sciences Corp.
E 32/100 β€” β€” -35.0% -4.20% $110.3M /avxl-vs-otlk β†’
ARMP
Armata Pharmaceuticals Inc.
E 32/100 β€” β€” -35.0% -13.11% $122.0M /armp-vs-otlk β†’
VYGR
Voyager Therapeutics Inc.
E 15/100 β€” β€” -35.0% +3.49% $106.0M /vygr-vs-otlk β†’

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K β€’ FILED 2025-09-30 β€’ CIK 0001649989 β†—

In its most recent audited fiscal period (FY2025, filed 2025-09-30), Outlook Therapeutics Inc. (OTLK) reported GAAP revenue of $1.4M (-99.3% vs. FY2024 revenue of $200.8M , and -99.0% cumulative change since FY2023) , GAAP net income of -$62.4M, operating cash flow of -$51.8M, and free cash flow of -$51.8M (+24.7% YoY). On the balance sheet, OTLK closed FY2025 with $18.2M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-09-30 $1.4M -$62.4M -$51.8M -$51.8M $18.2M β€”
FY2024 (FY) 2024-09-30 $200.8M -$75.4M -$68.8M -$68.8M $17.0M β€”
FY2023 (FY) 2023-09-30 $148.8M -$59.0M -$43.0M -$43.0M β€” β€”

3. OTLK Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

βœ“ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is OTLK stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, Outlook Therapeutics Inc. (NASDAQ: OTLK) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 35/100 at a spot price of $0.47 (+0.24% 1D, market cap $114.0M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 9/20, SEC Balance-Sheet Forensics 8/20, FRED Macro Regime Fit 7/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, OTLK ranks #599 in composite RQD confidence.

How does OTLK compare to HUMA and AVXL in the Health Care sector?

Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), OTLK carries a Roarable D- (35/100 RQD), trailing P/E of N/A, gross margin of 4.0%, and ROIC of -35.0%. By comparison, HUMA (Humacyte Inc.) holds a E grade (30/100 RQD, P/E N/A, ROIC -35.0%, cap $114.2M) and AVXL (Anavex Life Sciences Corp.) posts a E grade (32/100 RQD, P/E N/A, ROIC -35.0%, cap $110.3M). Among the 5-stock peer group, OTLK leads on earnings multiple (N/A) while OTLK leads on capital efficiency (-35.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for OTLK?

Per OTLK's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-09-30, CIK 0001649989), Outlook Therapeutics Inc. generated $1.4M in revenue (-99.3% YoY), -$62.4M in net income, and -$51.8M in free cash flow against $18.2M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

Where is OTLK trading relative to its 50-day, 200-day, and 52-week technical levels?

OTLK last traded at $0.47 (+0.24% on volume of 2,279,077 shares), positioning the stock -21.67% below its 50-day simple moving average ($0.60) and -28.79% below its 200-day simple moving average ($0.66). Across its 52-week range of $0.16 to $2.54, OTLK sits at the 13.0% percentile with a 14-day RSI of 37.0 (NEUTRAL RANGE) and an implied next-earnings move of Β±12.5% ($1.00 to $0.53).

Direct Sub-Reports: OTLK RQD Cockpit OTLK 12M Forecast OTLK Earnings & Move OTLK Dividends & DRIP OTLK Insiders & 13F OTLK Whale Options OTLK Profit Sankey OTLK News & Why
ROARABLE RATING BRIEF β€’ RQD 35/100 (D-) βœ“ SEC XBRL & RQD VERIFIED

OTLK β€” Outlook Therapeutics Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-09-30

1. Roarable Rating Brief: What This Means to a Prospective Investor

Outlook Therapeutics Inc. (OTLK) earns a live Roarable RQD composite score of 35/100, corresponding to a D- letter grade (Roarable Sell) at a spot price of $0.47 (+0.24% 1D, market capitalization $114.0M).

  • Fundamental Cash Engine (8/20): Anchored by return on invested capital (ROIC) of -35.0%, gross margin of 4.0%, operating margin of -60.0%, and free cash flow yield of β€”.
  • Whale 13F & Options Flow (9/20) + Insider Conviction (3/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (7/20) + Forensic Balance Sheet (8/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of 2/9, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

Outlook Therapeutics Inc. Is a NASDAQ-listed issuer in the Health Care sector, operating in the Biotechnology: Biological Products (No Diagnostic Substances) industry. Its market capitalization is $0.1B. FY 2025 revenue was $1.4M against FY 2024 and FY 2023 revenue of β€”.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-09-30), Outlook Therapeutics Inc. (OTLK) reported $1.4M in annual revenue (up from $200.8M in FY2024, -99.3% YoY) and -$62.4M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($148.8M revenue, -$59.0M net income) through FY2025, OTLK scaled operating cash flow to -$51.8M and free cash flow to -$51.8M, backed by $18.2M in total assets against $0 in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • πŸ‚ Primary Bull Case (D- β€’ RQD 35/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of β€” and institutional whale pillar of 9/20. With Fundamental Cash Engine at 8/20 and Institutional Whale Flow at 9/20, sustained execution supports upside toward the upper end of the $0.16 – $2.54 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against -60.0% operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

Operating in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), OTLK carries a macro regime beta of 1.00 and gross margin of 4.0%.

  • Key Question #1: Can OTLK sustain or expand its -60.0% operating margin and -35.0% ROIC against Biotechnology: Biological Products (No Diagnostic Substances) peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $1.4M and free cash flow of -$51.8M, how will capital allocation balance growth reinvestment against $0 in total debt?
  • Key Question #3: How sensitive is OTLK's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

OTLK Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Outlook Therapeutics Inc. (OTLK) β€’ Click "Debate This Headline" to argue it in the Roar Pit below

πŸ’¬ Jump to OTLK Debate Forum (3) ↓
πŸ”₯ THE ROAR PIT β€’ LIVE COMMUNITY DEBATE 3 Active Posts & Replies

OTLK Bull vs. Bear Conversation Board β€” What's Your Call at $0.47?

πŸ‚ 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON OTLK 🐻 33% BEARISH CONVICTION
1. Pick Your Side on OTLK:
πŸ’‘ Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
QU QuantViper RQD DEBATE OPENER β€’ Systematic Momentum Desk πŸ‚ BULLISH 🎯 Target: $0.55 (+17.0%)
πŸ“Œ Pinned Debate

Institutional accumulation and options positioning earn the highest pillar score at 11/20, the main offset to weak fundamentals.

Picked up a starter position in OTLK in my $100K Virtual Cash book at $0.47. Institutional accumulation and options positioning earn the highest pillar score at 11/20, the main offset to weak fundamentals.. Trading inside a $0.16–$2.54 52-week range with 0.0% FCF yield gives solid downside support if Biotechnology: Biological Products (No Diagnostic Substances) multiples expand this quarter.

CapAlloc_Nerd πŸ‚ BULL

@QuantViper Agree on the RQD 35/100 quality, though with 1.0 beta I'm scaling in with half-size at $0.47 and keeping dry powder in case we test $0.44.

RI RiskArb_Desk RQD DEBATE OPENER β€’ Hedged Event Driven 🐻 BEARISH 🎯 Target: $0.36 (-23.4%)
Spot @ $0.47

Negative ROIC of -35%, a 0% FCF yield, and a Piotroski F-Score of 2/9 leave the balance sheet and cash generation vulnerable.

Negative ROIC of -35%, a 0% FCF yield, and a Piotroski F-Score of 2/9 leave the balance sheet and cash generation vulnerable.. Look at the math on OTLK: paying current EV/EBITDA multiples for -35.0% ROIC and -60.0% operating margins leaves zero margin of safety if Biotechnology: Biological Products (No Diagnostic Substances) demand softens. I'd wait for a retest of $0.41 before getting long.

LIVE TAPE